Results 201 to 210 of about 12,502 (244)

Repetitive ambulatory levosimendan as a bridge to heart transplantation.

Revista Española de Cardiología, 2023
INTRODUCTION AND OBJECTIVES Repetitive ambulatory doses of levosimendan are an option as a bridge to heart transplantation (HT), but evidence regarding the safety and efficacy of this treatment is scarce.
J. D. J. Bagudá, F. Frutos, R. López-Vilella, D. Mallón, J. Guzman-Bofarull, Zorba Blázquez-Bermejo, Manuel Cobo-Belaustegui, C. Mitroi, F. Pastor-Pérez, C. Moliner-Abós, D. Rangel-Sousa, B. Díaz-Molina, Javier Tobar-Ruiz, N. S. González, José Manuel García-Pinilla, M. D. G. Carmena, M. Crespo-Leiro, D. Dobarro, L. Almenar, J. Delgado-Jiménez, E. Paredes-Galán, F. González-Vílchez, J. González-Costello   +22 more
semanticscholar   +1 more source

Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy.

Journal of Cardiothoracic and Vascular Anesthesia, 2022
OBJECTIVE This study was designed to compare the effects of levosimendan and dobutamine on hemodynamics and clinical efficacy in patients with severe septic cardiomyopathy (left ventricular ejection fraction [LVEF] ≤35%).
Tao Sun, Nan Zhang, N. Cui, Shen Wang, Xiaoxu Ding, Ning Li, Ning Chen, Zhanbiao Yu   +7 more
semanticscholar   +1 more source

Levosimendan’s effect on venoarterial extracorporeal membrane oxygenation weaning

International Journal of Artificial Organs, 2022
Background: Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) provides temporary haemodynamic support in refractory cardiogenic shock. Recent retrospective studies on levosimendan on V-A ECMO weaning had conflicting results.
M. Hau, K. Fong, S. Au
semanticscholar   +1 more source

Beneficial effects of levosimendan to wean patients from VA-ECMO: a systematic review and meta-analysis.

Minerva cardiology and angiology, 2022
INTRODUCTION Patients with refractory cardiogenic shock can benefit from veno-arterial extracorporeal membrane oxygenation (VA-ECMO). The use of levosimendan in VA-ECMO patients may facilitate weaning and enhance survival. EVIDENCE ACQUISITION MEDLINE,
P. Bertini, G. Paternoster, G. Landoni, M. Falcone, M. Nocci, Diego Costanzo, G. Brizzi, Matteo Romani, A. Esposito, F. Guarracino   +9 more
semanticscholar   +1 more source

Levosimendan

Reactions Weekly, 2021
  +4 more sources

Levosimendan Following Cardiac Surgery

Heart, Lung and Circulation, 2019
A best evidence topic was written to address if perioperative levosimendan improves mortality following cardiac surgery. Fourteen papers represented the best available evidence. An older meta-analysis summarising 11 of these trials concluded that there were fewer deaths in the levosimendan group compared to the control group (OR 0.41, p
Sean M, Conte, Daniel S, Florisson, Joshua A, De Bono, Reece A, Davies, Andrew E, Newcomb   +4 more
openaire   +2 more sources

Effects of levosimendan on the outcome of veno-arterial extracorporeal membrane oxygenation: a systematic review and meta-analysis

Clinical Research in Cardiology, 2023
Yuliang Liu, Li-chen Zhang, Yong Yao, Yihui Li, W. Qin, Yuan Li, W. Xue, Pengyong Li, Yuguo Chen, Xiaomei Chen, Haipeng Guo   +10 more
semanticscholar   +1 more source

Levosimendan

Reactions Weekly, 2016
Massimiliano Greco, Gianluca Paternoster, Daniela Mamo   +2 more
  +4 more sources

Levosimendan

Reactions Weekly, 2017
Vidyut Jain, Avani Jain
  +4 more sources

Levosimendan

Reactions Weekly, 2023
openaire   +2 more sources